Literature DB >> 2877605

Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995).

L B Barnard, W G Grantham, P Lamberton, T M O'Dorisio, I M Jackson.   

Abstract

Six patients with resistant acromegaly were given a long-acting somatostatin analogue (SMS 201-995) for 5 to 12 months. The clinical response was dramatic; relief of headache occurred within minutes of the injection. The mean 24-hour growth hormone levels fell acutely after the administration of 50 or 100 micrograms every 12 hours, especially in four patients with small tumors (p less than 0.001). Dosages of up to 1500 micrograms/d were necessary to produce maximum lowering of growth hormone secretion in some patients. On long-term treatment, plasma somatomedin-C levels fell in all patients and became normal in four. Plasma immunoreactive levels of SMS 201-995 related inversely to growth hormone concentration: A reproducible threshold for growth hormone inhibition in five of the patients, ranging from 70 to 1200 pg/mL, was maintained for 6 to 8 hours after the injections. This somatostatin analogue is effective in the treatment of acromegaly, has no major side effects, and causes only transient changes in carbohydrate metabolism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2877605     DOI: 10.7326/0003-4819-105-6-856

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  14 in total

1.  Molecular Events as Targets of Anticancer Drug Therapy.

Authors:  Adorján Aszalós; Sándor Eckhardt
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

Review 2.  Somatostatin agonists for treatment of acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Mol Cell Endocrinol       Date:  2007-11-29       Impact factor: 4.102

Review 3.  Acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

4.  Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer.

Authors:  A Manni; A E Boucher; L M Demers; H A Harvey; A Lipton; M A Simmonds; M Bartholomew
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

5.  Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal response to a mixed meal in acromegalic patients.

Authors:  R Candrina; A Gussago; G Giustina
Journal:  J Endocrinol Invest       Date:  1988-01       Impact factor: 4.256

6.  Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients.

Authors:  R Candrina; G Giustina
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

7.  Reduction in sella turcica volume. An effect of long-term treatment with the somatostatin analogue, SMS 201-995, in acromegalic patients.

Authors:  E Lund; J Jørgensen; S E Christensen; J Weeke; H Orskov; A G Harris
Journal:  Neuroradiology       Date:  1991       Impact factor: 2.804

8.  Long-term treatment with SMS 201-995 in resistant acromegaly: effectiveness of high doses and continuous subcutaneous infusion.

Authors:  G Mehltretter; S Heinz; J Schopohl; K von Werder; O A Müller
Journal:  Klin Wochenschr       Date:  1991-01-22

Review 9.  Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours.

Authors:  P Chanson; J Timsit; A G Harris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

Review 10.  Pharmacological therapy for acromegaly: a critical review.

Authors:  Alex F Muller; Aart Jan Van Der Lely
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.